Anti-Human GPC3 Recombinant Antibody (Codrituzumab) (CAT#: TAB-H14)

Figure 1 IA/L of serum was plotted following injection of 10 mg I-124 codrituzumab alone (circle) or co-infused with 2.5 mg/kg (triangles) or 5 mg/kg (squares).

The larger mass amount of antibody resulted in significant mass-dependent changes with longer half-life and greater AUC than the 10 mg injection (Table 2). There was an overlap of the clearance curves for the 2.5 and 5 mg/kg co-infused mass.

Carrasquillo, J. A., O’Donoghue, J. A., Beylergil, V., Ruan, S., Pandit-Taskar, N., Larson, S. M.,... & Abou-Alfa, G. K. (2018). I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI research, 8(1), 20.

Figure 2 Distributions of CD16 MESF across different GPC3 IHC scores.

It was also noted that the distributions of CD16 MESF across the four different GPC3 IHC categories (0, 1+, 2+, and 3+) are not significantly different.

Chen, G., Chen, Y. C., Reis, B., Belousov, A., Jukofsky, L., Rossin, C.,... & Di Laurenzio, L. (2018). Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget, 9(12), 10436.

Figure 3 Kaplan-Meier curves by joint GPC3 IHC high/low and CD16 MESF high/low status, where a GPC3-IHC high level is defined by GPC3 IHC = 2+, 3+, and a CD16-MESF high level is defined by CD16 MESF ≥ the median (363,594 MESF).

(A, B) Association between CD16 MESF level and codrituzumab treatment effect given a high level of GPC3 IHC. (C, D) Association between CD16 MESF level and codrituzumab treatment effect given a low level of GPC3 IHC.

Chen, G., Chen, Y. C., Reis, B., Belousov, A., Jukofsky, L., Rossin, C.,... & Di Laurenzio, L. (2018). Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget, 9(12), 10436.

Figure 1 Anti-GPC3 Antibody (TAB-H14) in WB

Western blot analysis of TAB-H14 was performed by loading Human GPC3 Protein (His Tag) in reduced condition Lane 1 and Lane 2 (20 ng and 50 ng) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-H14 (2 μg/mL) and HRP-conjugated goat anti-human IgG as a secondary antibody (1: 6000). Chemiluminescent detection was performed.

Figure 2 Anti-GPC3 Antibody (TAB-H14) in DB

Dot Blot analysis of TAB-H14 was performed by coating with Human GPC3 Protein (His Tag).

TAB-H14 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 6000)

Figure 3 Anti-GPC3 Antibody (TAB-H14) in ELISA

ELISA analysis of TAB-H14 was performed by coating with Human GPC3 Protein (His Tag). Then blocked with BSA and incubated with TAB-H14. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 5000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.